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CLINICAL INVESTIGATION
Effect of inorganic phosphate on serum ionized calcium
concentration in vitro: A reassessment of the
"trade-off hypothesis"
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Effect of inorganic phosphate on serum ionized calcium concentration
In vitro: A reassessment of the "trade-off hypothesis". The development
of secondary hyperparathyroidism in uremia is thought to be due, in
part, to the retention of inorganic phosphate which, as proposed by the
"trade-off hypothesis", lowers serum ionized calcium by means of
CaHPO4 complex formation. To study this hypothesis, free from
hormonal or physiological influence, the effect of changes in inorganic
phosphate concentration on calcium ion concentration was examined in
vitro in serum and protein-free aqueous solutions. The findings of this
study demonstrate that the mean change in ionized calcium in aqueous
solution is —0.019 0.001 m per 1 m change in inorganic phosphate,
and is not significantly different in serum where the mean change in
ionized calcium is —0.018 0.003 m per 1 m change in inorganic
phosphate. The results in both aqueous solutions and sera agree closely
with values predicted from the K'CaHPO4. Based on these results, the
serum inorganic phosphate would have to increase by 1.2 mai (3.7 mg%)
before the serum ionized calcium would fall sufficiently (0.025 mM) to
stimulate the parathyroid glands. These results indicate that an increase
in serum inorganic phosphate to as great as 1 mM/liter does not produce
a fall in serum ionized calcium by means of direct physicochemical
CaHPO4 complex formation great enough to account for the develop-
ment of secondary hyperparathyroidism.
Effet du phosphate inorganique sur Ia concentration du calcium ionisé
in vitro: une remise en question de l'hypothèse du "trade-or'. On
considère habituellement que le développement d'un hyperparathyroid-
isme secondaire au cours de l'insuffisance rénale chronique est dO en
partie a Ia retention de phosphore inorganique qui, ainsi qu'il est
propose par l'hypothèse du "trade-off", abaisse Ic calcium ionisC
sCrique par l'intermCdiaire d'une formation de CaHPO4. Afin d'étudier
cette hypothCse, en dehors de toute influence hormonale ou
physiologique, les effets de la modification de la concentration de
phosphore inorganique sur la concentration de l'ion calcium ont etC
CtudiCs in vitro dans du serum et des solutions aqueuses ne contenant
pas de protéines, Les résultats de cette étude montrent que la modifi-
cation moyenne du calcium ionisé dans la solution aqueuse est de
—0,019 0,001 mmoles pour une modification de 1 mmole du
phosphore inorganique, et n'est pas significativement diffCrente dans le
serum oü la modification moyenne du calcium ionisC est de —0,018
0,003 mmoles pour une modification de 1 mmole du phosphore
inorganique. Ces résultats, en solution aqueuse et dans le serum,
coincident étroitement avec ceux prédits d'après le K'CaHPO4. A partir
de ces rCsultats, on peut dire que Ic phosphore inorganique serique
devrait augmenter de 1,2 mmoles (3,7 mg%) avant que le calcium ionisé
et serique chute suffisamment (0,025 mmoles) pour stimuler les glandes
parathyroides. Ces rCsultats indiquent qu'une augmentation aussi
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grande que 1 mmole par litre de concentration sCrique du phosphore
inorganique ne provoque pas par le biais d'une formation de complexe
CaHPO4 une chute de concentration sérique de calcium ionisé suf-
fisante pour étre responsable du developpement d'une hyperparathy-
roidisme secondaire.
Phosphate retention is commonly associated with chronic
renal failure and has been implicated in the pathogenesis of
secondary hyperparathyroidism and renal osteodystrophy
[1—7]. The effect of hyperphosphatemia is thought to be medi-
ated by a reciprocal drop in serum ionized calcium attributed to
the formation of CaHPO4 complexes [2—10]. This concept was
first proposed in 1971 by Slatopoisky et al [21 and has since been
elaborated into the "trade-off hypothesis" by Bricker [5].
Briefly stated, this hypothesis maintains that as renal disease
advances, renal phosphate excretion falls; this results in small
elevations in serum inorganic phosphate (P1) which promote
CaHPO4 complex formation thereby resulting in small de-
creases in serum ionized calcium concentration ([Ca2]). This in
turn stimulates parathyroid hormone secretion which returns
phosphate excretion to normal, and corrects the serum P1
levels, but at the expense of secondary hyperparathyroidism
and renal osteodystrophy. This hypothesis led ultimately to the
widespread use of aluminum-containing phosphate binders in
patients with even moderate degrees of renal insufficiency.
The studies purporting to support this hypothesis are gener-
ally in vivo studies that demonstrate either a fall in serum
calcium levels with the infusion of phosphate [8—10] or the
prevention of secondary hyperparathyroidism by means of
phosphate restriction [2, 4, 6, 7]. The evidence in these studies
is suggestive, but the possible influence of hormonal or other
physiological factors are not addressed and cannot be excluded.
Moreover, studies in which phosphate was administered intra-
venously invariably raised the [Ca2] x [HP0421 product in
serum above the of CaHPO4 [8—10]. There are no specific
studies demonstrating a direct physiologically significant
physicochemical interaction between Ca2 and P1 in serum by
the order of magnitude proposed by the "trade-off" hypothesis.
In view of this, as well as the recent serious concerns regarding
the potential toxicity of aluminum, especially in patients with
renal failure, we examined in vitro the quantitative relationship
between P1 and Ca2 in serum.
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Methods
Solutions
Aqueous solutions were prepared using ultrapure reagent
grade water prepared by means of a Milli R.O. and Milli Q
water system (Worthington Diagnostics, Mfflipore, Bedford,
Massachusetts, USA) and contained 155 mM NaC1; 1 mM
Cad2; 0.1 m Tris-HCI, pH 7.40; and Na2HPO4 in concentra-
tions varying from I to 3 m.
Serum
Samples were obtained from seven healthy human volun-
teers, six males and one female, aged 28 to 60 years, and from
three separate batches of pooled human serum. Each sample of
blood was centrifuged at 4°C in polyethylene tubes containing a
5% C02/95% N2 gaseous environment. Five ml aliquots of
serum were removed and placed into individual tubes contain-
ing a similar gaseous environment plus 0.2 ml of a phosphate
solution consisting of Na2HPO4/NaH2PO4 in a ratio of 4:1 and in
a concentration calculated to increase the total [P1] from 0 to 8
m. Following 10 mm of equilibration and gentle mixing at
37°C, aliquots were removed and analyzed for pH and Ca2t
The remaining samples were then stored at 4°C and analyzed
within 2 to 48 hr for total Ca, P,, and Na. All determinations
were performed in triplicate and determinations for pH and
Ca2 were carried out at 37°C.
Analytical methods
Total calcium concentrations were determined by atomic
absorption spectrometry (IL Model 251, Instrumentation Lab-
oratories, Worthington, Massachusetts, USA). Ten percent
lanthanum was added to all samples. Coefficient of variation
(CV) was 1.2% for aqueous solution and 2.6% for serum.
Ionized calcium was determined with an Orion SS-220 ion
selective electrode (Orion Research, Cambridge, Massachu-
setts, USA) equipped with a neutral ligand ion exchange resin
and thermostatted at 37°C. Coefficients of variation were 1.4%
for aqueous solution and 2.5% for serum. Phosphate was
measured by standard autoanalyzer methods using a Techmcon
AAII autoanalyzer (Technicon, Tarrytown, New York, USA);
CV was 1.8% for aqueous solution and 2.8% for serum, and
sodium by flame photometry (IL Model 343); CV was 1.2% for
aqueous solution and 2.4% for serum.
Calculations
The concentration of complexed calcium in the aqueous
solution is defined as total [Cal — [Ca2]. The predicted
concentration of complexed Ca in aqueous solutions was cal-
culated from the equation for the dissociation constant for
CaHPO4 [11, 12]
—
[Ca2i [HP042]
—K CaHPO — ______________  0,02
[CaHPO4]
The [HP042] was calculated from the known K' for the
dissociation constants of NaHPO4 (0.23 M) and H2P04
(10-6.9 M) as described by Walser [13]. The for CaHPO4
used to determine which serum samples exceeded the solubiity
product for [aCa2} and [aHPO42] was 2.68 x i0 M2 [14].
1 2 3
Statistical analysis
All results are reported as mean SD. The results were
subjected to linear regression analysis by the method of least
squares and analysis of covariance was used to statistically
compare curves. Analyses were performed using a basic statis-
tical program on the TSR 80 Model II Microcomputer (Tandy
Corp., Fort Worth, Texas, USA).
Results
Effect of P, on ionized calcium concentrations in aqueous
solution
Increasing concentrations of P, from 0.955 0.02 to 2.970
0.06 m produced a progressive fall in ionized calcium concen-
tration (Fig. 1). The slope of the regression line is —0.019
0.001 (r =
—0.99). The observed concentrations for complexed
Ca at any given [P1] are considerably smaller than predicted
from the K' for CaHPO4; however, if the [HP042] is
corrected for interactions with Na and H, using the known
K's for NaHPO4 and H2PO4, the calculated concentrations of
complexed calcium agree very closely with the predicted values
(Table 1).
Effect of P on ionized calcium concentrations in serum
Increasing concentrations of P, from 0.84 to 8.11 m resulted
in a progressive fall in serum ionized calcium concentration
(Fig. 2). The slope of the regression line is —0.026 0.003 (r =
0.93), and is significantly steeper than that observed for an
aqueous solution (P < 0.05). These results were reanalyzed
using only those samples in which the [Ca2J x [Pj product did
not exceed the known for CaHPO4 in an aqueous solution
(Fig. 3). The slope of the new regression line is —0.018 0.006(r =
—0.84) and is not different from the value obtained in
aqueous solution.
Discussion
These results demonstrate that the change in [Ca2] in an
aqueous solution of 1 m CaCl2, ionic strength 0.15, is —0.019
0.001 ifiM per m of P, added. This value is smaller than that
predicted from the K' for CaHPO4 and is due to the fact that
there is an appreciable interaction between Na and HP042 in
the solution, thereby making less HPO42 available for
complexation with Ca2. If the [HP042] is calculated from the
known K' for NaHPO4, H2PO4, and CaHPO4 and is substi-
tuted for the total [PI], the slope of the regression line becomes
0
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Fig. 1. Relationship between the change in total [Pj and [CaJ in
aqueous solution, ionic strength 0.15, pH 7.39 .01; 37°C. Ca2 =
—0.019 (i Pj) + 0.007; r = —0.99.
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Table 1. Effect of inorganic phosphate on Ca2 in aqueous solutions
Calcium, mM/liter Phosphate, mM/liter Complexed Ca, mM/liter
Pi HP042Solutions Ca Ca2 Observed Predicteda
A .955 .023 .943 .008 .95 .01 .31 .01 .013 .012 .015 .001
B .955 .028 .928 .009 1.89 .05 .62 .01 .027 .016 .030 .001
C .955 .024 .904 .008 2.97 .02 .97 .02 .051 .019 .046 .001
All solutions were at ionic strength 0.155; pH 7.40 .01.
a Values calculated from dissociation constants for Ca HPO4, Na HP04, H2P04, as described in Methods.
N = 30 for cach solution.
1 2 3 4 5 6 7 8 9
.X P, mM/hter
Fig. 2. Relationship between the change in total [P/ and fCa'7 in
serum, pH 7.41 .01; 37°C. N = 27. Ca2 = —0.026 (i P1) — 0.0006;
r —0.92.
—0.058 00O2 and agrees closely with the values predicted
from the K' of CaHPO4.
The results obtained from pooled serum and the serum from
seven healthy volunteers demonstrate a mean fall in [Ca2] of
—0.026 0.003 mr'.'s per m increase of [P1]. This result is
significantly lower than that obtained in aqueous solutions;
however, the levels of [P1} used in the regression analysis
ranged from 0.84 to 8.11 m, and those values above 4.0 mM
exceeded the known of CaHPO4 in an aqueous solution. If
the regression analysis is performed using only those samples in
which values for [Ca2] and [P1] are below the theoretical of
CaHPO4, then a slope of —0.018 0.006 is derived, which is not
significantly different than the value obtained for an aqueous
solution.
Overall, these results would indicate that the relatively small
changes in P, concentration that regularly arise in the course of
mild to moderate chronic renal insufficiency and form the basis of
the "trade-off hypothesis" are incapable of inducing by direct
physicochemical means a decrease in serum [Ca2i of sufficient
magnitude to stimulate parathyroid hormone secretion. Studies on
the responsiveness of parathyroid cells to changes in [Ca2] report
a minimum sensitivity of 0.1 mg% (0.025 mM/liter) [151. Serum [P1]
would have to increase by approximately 3.7 mg% (1.2 mM/liter)
before this minimum fall in [Ca2] occurs. Moreover, by the time
renal failure is severe enough to manifest this degree of
hyperphosphatemia, significant changes in serum pH and
{HCO3i have occurred, both of which would tend to raise
independently the level of [Ca2]. The "trade-off" hypothesis as
proposed by Bricker [5] maintains that changes in [Ca2] large
enough to stimulate PTH secretion occur after very small or
virtually imperceptible rises in [P1]. This concept is clearly not
compatible with the results observed with serum in vitro or with
the known physicochemical relationship between Ca2 and
HP042 in aqueous solutions.
It should be emphasized, however, that these findings do not
1 2 3 4
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Fig. 3. Relationship between the change in total [Pj and [Ca247 in
serum in which (Ca2J x [HP042] was below the K of CaHPO4; pH
7.40 .01; 37°C. N = 15. z Ca2 = —0.18 ( P1) — 0.012; r = —0.84.
necessarily preclude the possibility that phosphate retention
and hyperphosphatemia are pathogenetically related to the
development of secondary hyperparathyroidism in uremia, only
that direct physicochemical mechanisms are not significantly
involved. The reciprocal relationship between calcium and
phosphorus, which is readily observed clinically, is likely the
consequence of multiply interrelated hormonal and physiologi-
cal mechanisms.
There is ample evidence that phosphate exerts a major
regulatory role in the metabolism of 1 ,25(OH)2D [16—19]. Mas-
sry et al [20, 21] first suggested that hyperphosphatemia might
induce hyperparathyroidism in uremia indirectly by diminishing
1 ,25(OH)2D levels and thereby reducing calcium absorption
from the intestine. This was subsequently confirmed by Mal-
luche, Werner, and Ritz [22] who demonstrated impaired intes-
tinal absorption in patients with mild to moderate renal insuffi-
ciency. More recently, Portale et al [23] reported that serum
iPTH varied directly and 1,25(OH)2D varied inversely with
dietary phosphorus in children with moderate renal disease
(GFR 45 4 mllmin). This study also noted that recurring
periods of postprandial hyperphosphatemia did not occur, as
had been proposed by Slatopolsky et al [3]. Finally, several
studies [24—26] have demonstrated a skeletal resistance to the
calcemic effect of PTH in uremia, thereby providing an addi-
tional mechanism for the development of hypocalcemia and
secondary hyperparathyroidism.
Although direct physicochemical interaction between Ca2
and HP042 in serum is unlikely to induce physiologically
significant hypocalcemia, it is possible that phosphate retention
in uremia may affect serum Ca2 levels indirectly by its effects
on bone. CaHPO4 nucleation, necessary for normal bone for-
mation, is an extremely complex process involving more than
simple electrochemical reactions between Ca2 and HP042.
Stereochemical reactions which involve the interaction of Ca2
and HP042 with phosphoprotein components of bone matrix
i
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are of great importance, and locally increased P1 could exert an
effect that would tend to ultimately lower serum calcium levels.
A number of studies have shown that increasing extracellular [P1]
in vitro inhibits both PTH-dependent and PTH-independent cal-
cium resorption from bone [27—291. Whether this is of physiolog-
ical significance in uremic osteodystrophy is not known.
In summary, this study demonstrates that changes in serum
phosphate levels of the magnitude proposed by the "trade-off
hypothesis" are incapable, solely by means of physicochemical
mechanisms, of lowering the ionized calcium concentration in
serum to the levels necessary to induce secondary hyperpara-
thyroidism. It is suggested that the early development of
secondary hyperparathyroidism in uremia must be the conse-
quence of a variety of complex metabolic and hormonal inter-
actions in which CaHPO4 complex formation is of little or no
significance.
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